RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
+0.84%Year over year
Reported trailing growth
- Revenue
- +198.5%
- EBITDA
- -50.9%
- EBIT
- -19.1%
- EPS
- +17.9%
- Free cash flow
- -15.7%
- Operating cash flow
- -15.1%
Forward estimates
Based on analyst estimates
- Revenue
- +222.2%
- EBITDA
- +16.6%
- EPS
- +31.2%
Three-year CAGR
- Revenue
- +2511.6%
- EBITDA
- -26.7%
- EBIT
- -14.0%
- Net income
- -26.7%
- EPS
- +13.5%
- Free cash flow
- -20.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026